Quantcast
Low Strength Brain Stimulation May Be Effective For

Low Strength Brain Stimulation May Be Effective For Depression

Elsevier B.V. Brain stimulation treatments, like electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS), are often effective for the treatment of depression. Like antidepressant medications, however, they typically have a...

Latest Antidepressant Stories

2014-07-21 10:08:09

Wolters Kluwer Health Study shows increased use of treatment and screening recommendations after three-step initiative A performance improvement initiative for physicians can significantly increase their use of evidence-based practices in screening for and treating depression, in the July Journal of Psychiatric Practice. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health. Led by Dr Michael E. Thase of the University of Pennsylvania Medical...

2014-07-15 16:27:44

LONDON, July 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023https://www.reportbuyer.com/product/2166742/Pristiq-Major-Depressive-Disorder---Forecast-and-Market-Analysis-to-2023.htmlPristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023SummaryMajor depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

2014-07-10 08:27:50

-- Sales Force Increased to Approximately 600 Sales Specialists -- SAN DIEGO, July 10, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600. Eisai expects this expansion of the sales force will enable them to increase their reach to approximately 92,000 physicians in...

2014-07-09 08:24:54

Three-part study explores challenges and opportunities facing the depression-treatment landscape a year after 25th anniversary of the U.S. launch of Prozac PHILADELPHIA, July 9, 2014 /PRNewswire/ -- The Intellectual Property and Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today released a three-part analysis on the depression drug market following the 25th anniversary of the U.S. launch of the iconic...

2014-06-25 08:32:39

Cognitive Deficit and Depression Symptoms Improve Significantly, Trial Data Shows GERMANTOWN, Md., June 25, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that two sets of data from the NSI-189 clinical trial in major depressive disorder (MDD) were reported at two recent academic conferences: American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, on June 17th, and the International College of Neuropyschopharmacology (CINP) Annual Meeting, on June 24th, 2014....

2014-06-24 08:29:42

Pharmacogenomic test now available to help guide clinicians' medication decisions for veterans being treated for mental health conditions MASON, Ohio, June 24, 2014 /PRNewswire/ -- Assurex Health today announced that the U.S. Department of Veterans Affairs (VA) has approved its Federal Supply Schedule (FSS) contract as a government supplier, effective June 15, 2014, making the GeneSight(®) Psychotropic test available for use in VA facilities nationwide. The Veterans Health...

2014-06-23 12:29:42

Data Highlight Physician and Payer Receptivity to Emerging Agents for Treatment-Resistant Depression, According to Findings from Decision Resources Group BURLINGTON, Mass., June 23, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. psychiatrists are receptive to novel adjunctive therapies to antidepressants for treatment-resistant depression (TRD) and would prescribe Otsuka/Lundbeck's emerging atypical antipsychotic brexpiprazole to a mean 12 percent of their drug-treated...

Tablet with a medicine
2014-06-19 10:33:25

Brett Smith for redOrbit.com - Your Universe Online In an attempt to raise awareness about a potential increased risk of suicide tied to antidepressant use, health officials may have made inadvertently made the problem worse. According to a new study in the British Medical Journal, FDA warnings about the increased risk of suicide and subsequent media coverage in 2003 were followed by a sudden drop in the number of prescriptions for antidepressants without compensation through increases...

2014-06-19 08:28:31

The New Website Offers Visitors Information About SSRIs and Autism, Autism Diagnoses, and How to Receive Compensation for Being Prescribed Autism-Inducing Medications HOUSTON, June 19, 2014 /PRNewswire-iReach/ -- Danziger & De Llano, LLP, a law firm whose main focus is to obtain justice for injured victims and their families, recently announced the launch of its new website, http://www.nationalautismclaims.com/. The law firm's latest site aims to provide help to children...

2014-06-17 13:13:51

American Society of Anesthesiologists Fast-acting ketamine by-product may be future therapy for Alzheimer's, Parkinson's There is new hope for people suffering from depression. Researchers have identified a compound, hydroxynorketamine (HNK), that may treat symptoms of depression just as effectively and rapidly as ketamine, without the unwanted side effects associated with the psychoactive drug, according to a study in the July issue of Anesthesiology, the official medical journal of...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related